European patent blow for coronavirus vaccine developer

21 November 2023
vaccine_shot_jab_booster_big

In the rush to develop effective vaccines against the novel coronavirus, several companies have sued, and counter-sued, for patent infringement, with potentially billions on the line.

Leading mRNA vaccine developers Pfizer (NYSE: PFE), BioNTech (Nasdaq: BNTX) and Moderna (Nasdaq: MRNA) are all subject to litigation in multiple jurisdictions.

The latest installment in this slow-moving clash of the titans is a decision from The European Patent Office, which invalidated a patent held by Moderna, causing the American biotech’s shares to trend downwards.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology